P. Jackson

发表

Distinct distal and proximal p53‐binding sites in the MCK promoter govern the transcriptional response to p53

P. Jackson, G. Yardley, Gina Yardley, 1997, FEBS letters.

Synergistic transcriptional activation of the MCK promoter by p53: tetramers link separated DNA response elements by DNA looping

P. Tegtmeyer, M. Reed, I. Mastrangelo, 1998, Oncogene.

Caffeine-increased radiosensitivity is not dependent on a loss of G2/M arrest or apoptosis in bladder cancer cell lines.

P. Jackson, J. Ribeiro, A. Barnetson, 1999, International journal of radiation biology.

An alternatively spliced KAI1 mRNA is expressed at low levels in human bladder cancers and bladder cancer cell lines and is not associated with invasive behaviour.

P. Jackson, M. Grimm, A. Rowe, 2007, Oncology reports.

Inverse correlation between KAI1 mRNA levels and invasive behaviour in bladder cancer cell lines.

P. Jackson, P. Russell, E. Kingsley, 2000, Cancer letters.

Androgen decreases osteoprotegerin expression in prostate cancer cells

K. Vandyke, P. Jackson, P. Russell, 2007, Prostate Cancer and Prostatic Diseases.

Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines.

K. Pienta, R. Loberg, P. Jackson, 2004, Cancer letters.

KAI1 tetraspanin and metastasis suppressor.

P. Jackson, P. Russell, A. Marreiros, 2005, The international journal of biochemistry & cell biology.

Phorbol ester enhances KAI1 transcription by recruiting Tip60/Pontin complexes.

P. Jackson, O. Huber, J. Weiske, 2008, Neoplasia.

Phorbol Ester Enhances KAI1 Transcription by Recruiting

P. Jackson, O. Huber, 2008 .

No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.

K. Byth, J. Nesland, M. Friedlander, 2004, Gynecologic oncology.

Down-regulation of KAI1/CD82 protein expression in oral cancer correlates with reduced disease free survival and overall patient survival.

P. Jackson, K. Ow, P. Russell, 2004, Cancer letters.

Transcriptional regulation of the PCNA promoter by p53.

J. Rayner, A. Braithwaite, P. Jackson, 1994, Biochemical and biophysical research communications.

Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer

P. Jackson, J. Barrett, K. Ow, 2000, The Journal of pathology.

Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers.

P. Jackson, G. Yardley, J. Barrett, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression. a review of the evidence.

S. Downing, P. Jackson, P. Russell, 2001, Urologic oncology.

Identification of regulatory regions within the KAI1 promoter: a role for binding of AP1, AP2 and p53.

P. Jackson, G. Yardley, A. Marreiros, 2003, Gene.

KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells

P. Jackson, M. Grimm, A. Marreiros, 2005, Oncogene.

Methylation of a CpG island within the uroplakin Ib promoter: a possible mechanism for loss of uroplakin Ib expression in bladder carcinoma.

P. Jackson, A. Marreiros, P. Cowled, 2004, Neoplasia.

Methylation of a CpG island within the promoter region of the KAI1 metastasis suppressor gene is not responsible for down-regulation of KAI1 expression in invasive cancers or cancer cell lines.

S. Clark, P. Jackson, G. Yardley, 2000, Cancer letters.

An inverse relationship between KAI1 expression, invasive ability, and MMP-2 expression and activity in bladder cancer cell lines.

P. Jackson, M. Madigan, P. Russell, 2012, Urologic oncology.

Uroplakin Ib gene transcription in urothelial tumor cells is regulated by CpG methylation.

P. Jackson, P. Cowled, I. Kanter, 2005, Neoplasia.

Is the KAI1 metastasis suppressor gene a cellular target of p53? A review of current evidence.

A. Puisieux, P. Jackson, 2000, Biochemical and biophysical research communications.

Development and classes of epigenetic drugs for cancer.

P. Jackson, D. Dhanak, 2014, Biochemical and biophysical research communications.

Individual promoter and intron p53‐binding motifs from the rat Cyclin G1 promoter region support transcriptional activation by p53 but do not show co‐operative activation

M. Oren, P. Jackson, Gina Yardley, 1998, FEBS letters.

Endothelial glucocorticoid receptor promoter methylation according to dexamethasone sensitivity

P. Jackson, Lubo Zhang, E. Mata-Greenwood, 2015, Journal of molecular endocrinology.

Elevated levels of prostate‐specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis

S. Downing, P. Jackson, K. Ow, 2003, Molecular carcinogenesis.

Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with p53 overexpression

P. Jackson, G. Yardley, K. Ow, 2003, Prostate Cancer and Prostatic Diseases.

Relationship between expression of KAI1 metastasis suppressor gene, mRNA levels and p53 in human bladder and prostate cancer cell lines.

P. Jackson, G. Yardley, M. Grimm, 2002, Urologic oncology.

p53-dependent activation of the mouse MCK gene promoter: identification of a novel p53-responsive sequence and evidence for cooperation between distinct p53 binding sites.

M. Reed, A. Braithwaite, P. Jackson, 1995, Gene expression.

Wild-type mouse p53 down-regulates transcription from different virus enhancer/promoters.

A. Braithwaite, P. Jackson, E. Bos, 1993, Oncogene.

Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo.

P. Vermeulen, P. Jackson, K. Ow, 2006, Biochemical and biophysical research communications.

Expression of the KAI1 metastasis suppressor gene in non-metastatic versus metastatic human colorectal cancer.

P. Jackson, P. Russell, Yan Yu, 2002, Anticancer research.

Regulation and deregulation of G2 checkpoint proteins with cisplatin.

P. Jackson, J. Ribeiro, M. Links, 1998, Anticancer research.

p53 represses SV40 transcription by preventing formation of transcription complexes.

J. Rayner, A. Braithwaite, P. Jackson, 1995, Oncogene.

Expression of KITENIN, a KAI1/CD82 binding protein and metastasis enhancer, in bladder cancer cell lines: relationship to KAI1/CD82 levels and invasive behaviour.

P. Jackson, A. Rowe, 2006, Oncology reports.

Prostate Cancer: Methods and Protocols

P. Jackson, P. Russell, E. Kingsley, 2018 .

Alterations of p53 are common in early stage prostate cancer.

S. Downing, P. Jackson, P. Russell, 2003, The Canadian journal of urology.

Differential expression analysis of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell biology.

K. Pienta, R. Loberg, P. Jackson, 2005, International Journal of Oncology.